UK-India trade deal sparks fears over access to cheap medicines for millions
Civil society groups and health experts say the UK-India Free Trade Agreement (FTA), finalised between two countries, tilts the balance in favour of multinational pharmaceutical corporations and threatens to erode long-standing protections that have allowed India to produce low-cost generic drugs.
'This is not just about trade. It's about whether a person living on ₹200 (£2) a day can afford cancer treatment or survive tuberculosis,' said Jyotsna Singh, co-convenor of the Working Group on Access to Medicines and Treatments.
At the heart of the controversy are the agreement's intellectual property (IP) provisions, which activists say may restrict the Indian government's ability to issue compulsory licences—legal tools that allow domestic companies to manufacture patented drugs at reduced prices during public health emergencies.
India used this provision in 2012 to dramatically cut the price of sorafenib, a cancer drug sold by Bayer under the brand Nexavar.
Generic versions slashed the monthly cost by nearly 97%, from ₹2.8 lakh (£2,600) to around ₹8,800 (£80), making it affordable to thousands.
'By discouraging compulsory licensing and promoting voluntary licences, the deal hands over control of access to medicines to the market,' said Prof Biswajit Dhar, a trade expert and former professor at New Delhi's Jawaharlal Nehru University.
'Voluntary licences often come with strings attached and don't bring the same price reductions.'
Weakening India's Patent Safeguards
Under the FTA, companies will no longer need to report annually how their patents are being 'worked'—or used—in India.
Instead, disclosures can be made every three years, and some information can be kept confidential.
Activists say this undermines transparency and makes it harder to prove that a drug isn't available to the public, a key step in applying for a compulsory licence.
There are also concerns the deal could open the door to 'evergreening'—a tactic in which companies make minor changes to existing drugs and claim new patents.
Indian law currently limits this practice under Section 3(d) of the Patents Act, but experts warn the FTA's emphasis on 'harmonisation' of IP standards with Western countries could override such protections.
'This is effectively a backdoor entry for TRIPS-plus provisions,' said K.M. Gopakumar, co-convenor of the Working Group.
'It would push India to grant unnecessary patents, prolonging monopolies and delaying cheaper alternatives.'
The Indian pharmaceutical industry supplies more than 60% of global vaccines and a significant share of affordable generics to low- and middle-income countries.
Critics say the FTA may limit this capacity and ultimately have consequences well beyond India's borders.
Government response
The Indian government has promoted the FTA as a landmark deal that will boost exports and attract UK investment in manufacturing, services, and digital trade.
Officials insist that India has preserved its ability to protect public health.
But rights groups remain unconvinced.
'You cannot negotiate away access to life-saving drugs in the name of free trade,' said Gargeya Telakapalli, a public health campaigner based in Hyderabad.
'The poorest Indians—those with cancer, HIV, diabetes, or TB—are being quietly sacrificed.'
Broader implications
The deal follows a similar agreement India signed last year with the European Free Trade Association (EFTA), which also faced criticism for diluting IP safeguards.
Observers say the trend may reflect a shift in India's trade policy as it seeks closer ties with Western economies.
But for many in India's healthcare and legal communities, the question remains: how much access to medicine is the country willing to give up for a better trade balance?
From Westminster to Washington DC - our political experts are across all the latest key talking points. Listen to the latest episode below...
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Independent
15 minutes ago
- The Independent
Patients whose lives were ruined after being ‘needlessly given cancer drug for years' sue NHS trust
More than 20 patients who say their quality of life was wrecked when they were needlessly given a highly toxic cancer drug are suing the NHS trust involved. Some people were prescribed temozolomide – which should normally be used for only six months – for more than a decade during treatment by the University Hospitals Coventry and Warwickshire NHS Trust. They say the overprescribing left them with side-effects including secondary cancers and crippling fatigue. Earlier this year the Care Quality Commission was looking into at least 14 cases, but lawyers say more are emerging all the time. An investigation by lawyers Brabners found that, over the past two decades, numerous patients with brain and spinal tumours under the care of Professor Ian Brown were routinely exposed to prolonged and in some cases 'unnecessary' use of the chemotherapy drug, which has severe side-effects including extreme fatigue, confusion, sickness and seizures. The time periods temozolomide was given for allegedly ran contrary to medical and scientific guidelines. Standard NHS procedure is to use the drug over six months, and the drug manufacturer advises it be used for up to 12 months. One man said he was prescribed it for nearly two years longer than necessary, suffering extreme fatigue and low mood as a result. A woman in her twenties said she was misdiagnosed with cancer, receiving the drug needlessly for about eight years. Some patients are now having treatment for secondary cancers allegedly linked to overuse of temozolomide, the lawyers claim. Others claimed its prolonged use left them unable to pursue career ambitions and normal day-to-day activities because the chemotherapy was debilitating, with a long recovery time. Some reported loss of fertility or abnormal blood test results. The legal team says data shows that the trust's spending on the drug of £3.6m from 2009 to 2024 is 10 times that of other NHS oncology departments. The lawyers are now calling for an extended patient safety review and independent investigation, focusing in particular on treatment received by patients under Prof Brown dating back to 2006. The trust has been conducting an internal patient safety review, covering 2017 to 2023, when Prof Brown retired. A patient who identified only as Michael received an extra 22 cycles of temozolomide at the trust, despite his scans being stable. Prof Brown was not present during consultations, and Michael said he was always seen by a clinical nurse specialist. After suffering extreme fatigue and low mood, he learnt through news reports of mistreatment –not from the trust – that he should not have remained on treatment for so long, according to his lawyers. Another patient, identified only as Becky, says she received at least 100 cycles of the drug unnecessarily after being misdiagnosed with a brain tumour. Fiona Tinsley, head of medical negligence at Brabners, said: 'The extent of this scandal, and the physical and mental impact it has had on Prof Brown's patients cannot be underestimated.' She added: 'We believe there are many more patients out there who haven't yet come forward and some who may have sadly passed away. 'While we welcome the ongoing investigations being undertaken by the General Medical Council and Royal College of Physicians, we believe a full independent inquiry is necessary – including an extension of the trust's own review back to 2006 – not only to ensure justice for victims, but that processes are put in place to better identify and prevent such failings happening again.' A spokesperson for the trust told The Independent: 'We have comprehensively reviewed and spoken to all individuals who were receiving temozolomide (TMZ) treatment at the end of 2023 to ensure appropriate support and care plans are in place. 'A glioblastoma is an aggressive brain tumour with fewer than two per cent of patients surviving longer than 10 years. This is an extremely complex condition and all modes of treatment – surgery, chemotherapy and radiotherapy – carry the risk of complications and side-effects. 'National Institute for Health and Care Excellence (Nice) guidelines recognise that clinicians can exercise professional judgment appropriate to individual circumstances when offering treatment to patients. 'We have commissioned the Royal College of Physicians to conduct an independent review of a representative cohort of patients who received greater than 12 cycles of adjuvant TMZ between 2017 and 2023. 'As this process is ongoing, it would be inappropriate to comment further at this stage." It's understood that CQC inspectors have been in touch with the trust to understand the details, and seek assurances that patients are not at risk. The regulator will be reviewing more information to judge whether it needs to be involved.
Reuters
16 minutes ago
- Reuters
Doordash forecasts strong quarter on resilient delivery demand
Aug 6 (Reuters) - Doordash (DASH.O), opens new tab forecast third-quarter gross merchandise value above Wall Street expectations after topping estimates on Wednesday, betting on robust demand for food and grocery deliveries through its platform. The company's offers and promotions, particularly in its U.S. and international markets for members, has attracted budget-conscious consumers seeking value to its online services. Doordash expects gross merchandise value, a measure of the total dollar value of orders placed through its platform, to be between $24.2 billion and $24.7 billion for the current quarter, above estimates of $23.73 billion, according to estimates compiled by LSEG. Doordash's shares were up 6% in extended trading after the company also topped estimates for second-quarter revenue and gross merchandise value. The company also reiterated its expectations for its purchase of U.K. rival Deliveroo (ROO.L), opens new tab to close in the fourth quarter. Doordash has expanded its online delivery options beyond food to groceries, alcohol, electronics and beauty products, boosting sales while restaurants battled sluggish demand amid economic uncertainty. Gross merchandise value rose 23% to $24.2 billion in the quarter ended June 30, beating estimates of $23.58 billion, with total orders climbing 20% year-over-year. Total revenue of $3.28 billion for the reported three-month period also beat estimates of $3.16 billion. Net revenue margin inched higher to 13.5% from 13.3% a year ago, helped by robust advertising revenue. Rival UberEats' parent Uber (UBER.N), opens new tab also forecast a strong third quarter earlier in the day, banking on robust demand for ride-hailing and deliveries.
Daily Mail
16 minutes ago
- Daily Mail
Taxman's guilt at being British: Fury as HMRC, which can't even answer your phone calls, allows staff event, held during office hours, discussing the 'Guilt of Being British'
Civil servants working for the taxman has come under fire after holding a seminar on the 'Guilt of Being British'. Staff at HM Revenue and Customs were able to log-in remotely and attend the session during office hours yesterday, prompting a furious backlash. It comes amid repeated criticism of HMRC 's performance, with hundreds of thousands of calls from taxpayers going unanswered every month, customers getting surreptitiously cut off, and general concern from MPs over the 'failing' phone service. Kemi Badenoch on Wednesday night described the session as 'nonsense', and challenged Whitehall aides to leave the service if they were not proud of Britain. The Tory leader told the Mail: 'Is it any wonder the public hate dealing with HMRC, now we learn the staff are being taught to feel guilty about being British? 'In government I fought to remove all this nonsense from the Civil Service. Under my leadership, a Conservative government will ensure public bodies are proud of Britain, not ashamed of it. 'We'll defend our history, not apologise for it. And if that offends the Civil Service's seminar circuit, they're welcome to go somewhere else.' The hour-long 'Guilt of Being British: Listening circle' was run by the HMRC Race Network and held from 11am until midday. It was billed as 'a powerful, interactive, and reflective listening circle exploring the emotional complexity of being South Asian and British', covering topics including 'the emotional weight of colonial history' as part of the taxman's commitment to diversity, equality and inclusion. According to a post published on the HMRC's intranet, the session promised to 'delve into themes of guilt, pride, and identity, offering space for personal stories and cultural insights'. Workers were told participants would explore 'the duality of identity - balancing heritage and belonging', and the 'emotional weight of colonial history and inherited trauma'. The internal advert said those attending would discover more about 'career challenges faced by South Asian women - barriers, bias and expectations', and learn how 'storytelling and representation help reclaim our narratives.' A dumbfounded Civil Service source told the Mail: 'This example of a work-time staff event pushing a highly divisive anti-British narrative perfectly encapsulates the nightmare that is Civil Service staff networks. 'Those focused on race and trans in particular seem to operate entirely without scrutiny, and attract large numbers of activist staff, intent on pushing their personal beliefs on their colleagues rather than identifying and tackling actual workplace issues. 'This is a total abandonment of the vital principle of Civil Service political neutrality and makes a lot of us very uncomfortable, but if you challenge these groups on their approaches you risk putting a target on your back. 'As is seen in this event, these networks also enable many people to treat the workplace like their personal therapy centres. 'So many of us are getting on with our jobs and we see colleagues holding listening circles to talk about personal traumas - it fosters resentment and damages public trust.' Sir Jacob Rees-Mogg, the former Tory Cabinet Minister, added: 'It is peculiar that people who hate their country want to run it. 'Perhaps I should offer a course on why being British is to win first prize in the lottery of life.' Joanna Marchong, investigations campaign manager at the TaxPayers' Alliance, said: 'Taxpayers are fed up of bankrolling woke staff networks. 'While HMRC quangocrats sit around in circles whining about colonialism, hard-working Brits are being left on hold for hours on end. 'Staff networks should not be funded by taxpayers and they certainly shouldn't be happening during working hours.' It is not known how many of HMRC's more than 60,000 staff attended the remote event. A spokesman for the taxman said it would have been less than 0.1% and had no impact on its call handling ability. Earlier this year a report by Parliament's Public Accounts Committee found HMRC answered just 66.4 per cent of customers' attempts to speak to an adviser, well below the target of 85 per cent. It said performance reached 'an all-time low'. Around 40,000 customers were cut off in the year 2023-24 if they were waiting for more than 70 minutes, without an explanation, and no callback option was available. The average call wait time exceeded 23 minutes, with HMRC saying it did not have adequate resources to meet telephone demand from customers. The report said: 'HMRC's already poor service to taxpayers has become even worse. 'The PAC is concerned that HMRC has degraded its own phone services - willing to let them fail, in the hope that people will be forced to go online.' HMRC's most recent monthly performance report, however, shows signs of improvement - 80 per cent of calls were handled in March, while average call time waits were down to 14 minutes and 44 seconds. An HMRC spokesman said: 'Events by staff networks should not be taken as reflecting the views of HMRC. 'An event like this would only be attended by around 0.1% of staff, which would have no impact on our ability to staff our helplines. We have robust processes in place to ensure our phonelines are well-resourced throughout the day.' It comes after the Mail last week revealed the NHS budgeted nearly £2 million for similar staff networks in the health service, many of whom hold 'woke' events for staff. They included an event on 'Embracing Asexuality', a talk on 'Embracing your Afro/Curly hair' and another on 'International Pronouns Day'.
